Search results
Showing 8656 to 8670 of 9039 results
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
In development Reference number: GID-HST10037 Expected publication date: TBC
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Discontinued Reference number: GID-TA10961
Discontinued Reference number: GID-TAG390
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]
Discontinued Reference number: GID-TA11522
In development Reference number: GID-TA11745 Expected publication date: TBC
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
Discontinued Reference number: GID-TAG363
Discontinued Reference number: GID-TA10144
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
This guidance has been replaced by NICE guideline NG17.
NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed
Around 530 people in England will benefit from access to the Duchenne muscular dystrophy treatment givinostat, following the successful negotiation of a commercial deal to make the medicine available on the NHS.
NICE joins international collaboration on HTA methods research
We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.
'I no longer feel asthmatic': more than a million people now using new style inhalers
The change follows a landmark guideline published jointly in 2024 by NICE, the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN).
Injection for more than a million people to help prevent heart attacks and strokes recommended
People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.
NICE appoints Dr Adrian Hayter as its new chief medical officer
Dr Adrian Hayter joins NICE from the Royal College of General Practitioners bringing more than three decades of frontline clinical and national leadership experience to the role.
Endometriosis fertility care and gynaecological cancer guidance
Home News Podcasts Endometriosis fertility care and gynaecological cancer guidance Podcasts 01 May 2026 Listen About this episode For the